Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | MMP3 | P08254 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615482 | 0.82 | BMP1 (0.55) | SMN1; SMN2LMNAHTTRAB9ANPC1 | |
| SCHEMBL12896231 | 0.76 | LMNA (0.66) | CNR2MMP3SMN1; SMN2LMNAHTT | |
| SCHEMBL398044 | 0.76 | CNR2 (0.57) | CNR2SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL3626535 | 0.74 | CA12 (0.50) | CNR2SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL4076826 | 0.73 | CA12 (0.57) | CNR2SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL20314702 | 0.73 | MMP3 (0.46) | CNR2MMP3SMN1; SMN2LMNAHTT | |
| SCHEMBL3619711 | 0.72 | CNR2 (0.49) | CNR2SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL344199 | 0.72 | FFAR4 (0.50) | CNR2MMP3SMN1; SMN2LMNAMMP2 | |
| SCHEMBL26212922 | 0.72 | ALDH1A1 (0.51) | MMP3SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL930312 | 0.72 | PKM (0.58) | CNR2MMP3SMN1; SMN2HTTMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2407453-A1 | PGD2 receptor antagonist | Shionogi & Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2407459-A1 | Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity | Shionogi & Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-1939175-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi&Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | CNR2 3/4885MMP3 2762/4885SMN1; SMN2 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.